Development of a highly sensitive method for the quantification of estrone and estradiol in serum by liquid chromatography tandem mass spectrometry without derivatization

Fiers, Tom; Casetta, Bruno; Bernaert, Brigitte; Vandersypt, Eric; Debock, Martine; Kaufman, Jean‐Marc

doi:10.1016/j.jchromb.2012.02.034

Cited by 115 publications

(73 citation statements)

References 28 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We use a prospective controlled design, which has, to our knowledge, not been reported in trans persons allowing the differentiation of changes due to aging or treatment. LCMS/MS was used for the determination of sex steroids, which has the required the sensitivity for assay of low ranges of E 2 , as found in trans men on testosterone therapy (16).…”

Section: Discussionmentioning

confidence: 99%

“…Testosterone and estradiol (E 2 ) were determined by liquid chromatrography-mass spectrometry (LCMS/MS) on an AB Sciex 5500 triple-quadrupole mass spectrometer (AB Sciex, Toronto, ON, Canada) (16). Commercial immunoassays were used to determine the serum concentrations of luteinizing hormone (LH), follicle-stimulating hormone (FSH), 25-hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH), C-terminal telopeptides of type 1 collagen (CTX) (bone resorption) (Modular, Roche Diagnostics), procollagen 1 aminoterminal propeptide (P1NP) (bone formation) (Cobas 411, Roche Diagnostics), and IGF1 (Cisbio bioassays, Codolet, France).…”

Section: Biochemical Determinationsmentioning

confidence: 99%

See 1 more Smart Citation

Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case–controlled study (ENIGI)

Caenegem

Wierckx

Taes

et al. 2015

European Journal of Endocrinology

123

106

View full text Add to dashboard Cite

Purpose: To assess the evolution of body composition and bone metabolism in trans men during the first year of cross-sex hormonal therapy. Methods: In a prospective controlled study, we included 23 trans men (female-to-male trans persons) and 23 age-matched control women. In both groups, we examined grip strength (hand dynamometer), biochemical markers of bone turnover (C-terminal telopeptides of type 1 collagen (CTX) and procollagen 1 aminoterminal propeptide (P1NP)), total body fat and lean mass, and areal bone mineral density (aBMD) by dual-X-ray absorptiometry (DXA) and fat and muscle area at the forearm and calf, bone geometry, and volumetric bone mineral density (vBMD) by peripheral quantitative computed tomography (pQCT), before treatment and after 1 year of treatment with undecanoate (1000 mg i.m./12 weeks). Results: Before hormonal treatment, trans men had similar bone and body composition compared with control women. Testosterone treatment induced in trans men a gain in muscle mass (C10.4%) and strength and loss of fat mass (K9.7%) (all P!0.001) and increased the levels of P1NP and CTX (both P!0.01). Areal and volumetric bone parameters remained largely unchanged apart from a small increase in trabecular vBMD at the distal radius and in BMD at the total hip in trans men (PZ0.036 and PZ0.001 respectively). None of these changes were observed in the control group. Conclusions: Short-term testosterone treatment in trans men increased muscle mass and bone turnover. The latter may rather reflect an anabolic effect of testosterone treatment rather than bone loss.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Biochemical Determinationsmentioning

confidence: 99%

Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case–controlled study (ENIGI)

Caenegem

Wierckx

Taes

et al. 2015

European Journal of Endocrinology

123

106

View full text Add to dashboard Cite

show abstract

“…Following 6 wk of treatment employing the initially placed osmotic minipump (at 12 wk of age), the first minipump was removed, and it was replaced with a second minipump to continue the same treatment for an additional 6 wk. Effective delivery of E2 (1.6 g/day) via the minipump was evaluated in a parallel experiment that entailed serum sampling just before the 6-wk time point, E2 isolation from serum by solid phase extraction, and analysis by LC-MS using electrospray ionization in the negative mode (18). Serum E2 was 40 Ϯ 8 pg/ml in the mice administered E2 compared with 8 Ϯ 2 pg/ml in vehicletreated mice (means Ϯ SE, n ϭ 9/group, P Ͻ 0.05).…”

Section: Methodsmentioning

confidence: 99%

Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract

Barrera

Chambliss

Ahmed

et al. 2014

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

gated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract. Am J Physiol Endocrinol Metab 307: E345-E354, 2014. First published June 17, 2014 doi:10.1152/ajpendo.00653.2013.-Despite the capacity of estrogens to favorably regulate body composition and glucose homeostasis, their use to combat obesity and type 2 diabetes is not feasible, because they promote sex steroid-responsive cancers. The novel selective estrogen receptor modulator (SERM) bazedoxifene acetate (BZA) uniquely antagonizes both breast cancer development and estrogen-related changes in the female reproductive tract. How BZA administered with conjugated estrogen (CE) or alone impacts metabolism is unknown. The effects of BZA or CE ϩ BZA on body composition and glucose homeostasis were determined in ovariectomized female mice fed a Western diet for 10 -12 wk. In contrast to vehicle, estradiol (E2), CE, BZA, and CE ϩ BZA equally prevented body weight gain by 50%. In parallel, all treatments caused equal attenuation of the increase in body fat mass invoked by the diet as well as the increases in subcutaneous and visceral white adipose tissue. Diet-induced hepatic steatosis was attenuated by E2 or CE, and BZA alone or with CE provided even greater steatosis prevention; all interventions improved pyruvate tolerance tests. Glucose tolerance tests and HOMA-IR were improved by E2, CE, and CE ϩ BZA. Whereas E2 or CE alone invoked a uterotrophic response, BZA alone or CE ϩ BZA had negligible impact on the uterus. Thus, CE ϩ BZA affords protection from diet-induced adiposity, hepatic steatosis, and insulin resistance with minimal impact on the female reproductive tract in mice. These combined agents may provide a valuable new means to favorably regulate body composition and glucose homeostasis and combat fatty liver. bazedoxifene; conjugated estrogen; hepatic steatosis; obesity; type 2 diabetes IN ADDITION TO THEIR ROLES in sexual development and reproduction, estrogens contribute to the regulation of body weight and body composition and to glucose homeostasis. Insulin sensitivity is greater in women prior to menopause vs. agematched men (16,42), in women the risk for weight gain and for the development of type 2 diabetes increases with the decline in the levels of estrogens that occurs at menopause, and menopause favors an increase in total body fat and visceral fat deposition (4). In addition, hormone replacement therapy with conjugated estrogen (CE) and medroxyprogesterone acetate (MPA) in postmenopausal women causes a 21-35% decrease in diabetes occurrence (29,35). Furthermore, in female rodents and primates, ovariectomy results in impaired insulin sensitivity and glucose homeostasis, and these effects are reversed by estradiol (E 2 ) (30, 54). Studies in mice have additionally demonstrated that E 2 provides potent protection against highfat diet-induced glucose intolerance and insulin resistance (46). The metabolic actions of estrogens are mediated primarily by estrogen receptor (E...

show abstract

“…Achieving the necessary sensitivity using LC-MS/MS without resorting to complex derivatization methods has been a challenge but the discovery of using trace amounts of ammonium fluoride in the mobile phase has enabled the development of assays capable of measuring as low as 10 pmol/l (33,34), which is suitable for the vast majority of samples. However, we have still not reached the required sensitivity of 1 pg/ml (3.7 pmol/l) advocated in the Endocrine Society position statement (35) and because these methods require expensive high sensitivity MS instruments, it may be some time before they are used universally.…”

Section: Commonly Requested Steroidsmentioning

confidence: 99%

Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow

Taylor¹,

Keevil²,

Huhtaniemi³

2015

European Journal of Endocrinology

242

157

View full text Add to dashboard Cite

SummaryThe recent onslaught of mass spectrometry (MS) to measurements of steroid hormones, including demands that they should be the only acceptable method, has confused clinicians and scientists who have relied for more than 40 years on a variety of immunoassay (IA) methods in steroid hormone measurements. There is little doubt that MS methods with their superior specificity will be the future method of choice in many clinical and research applications of steroid hormone measurement. However, the majority of steroid measurements are currently, and will continue to be, carried out using various types of IAs for several reasons, including their technical ease, cost and availability of commercial reagents. Speedy replacement of all IAs with MS is an unrealistic and unnecessary goal, because the availability of MS measurements is limited by cost, need of expensive equipment, technical demands and lack of commercial applications. Furthermore, IAs have multiple well-known advantages that vindicate their continuing use. The purpose of this article is to elucidate the advantages and limitations of the MS and IA techniques from two angles, i.e. promotion of MS and defence of IA. The purpose of the text is to give the reader an unbiased view about the current state and future trends of steroid analysis and to help him/her choose the correct assay method to serve his/her diagnostic and research needs.

show abstract

Development of a highly sensitive method for the quantification of estrone and estradiol in serum by liquid chromatography tandem mass spectrometry without derivatization

Cited by 115 publications

References 28 publications

Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case–controlled study (ENIGI)

Body composition, bone turnover, and bone mass in trans men during testosterone treatment: 1-year follow-up data from a prospective case–controlled study (ENIGI)

Bazedoxifene and conjugated estrogen prevent diet-induced obesity, hepatic steatosis, and type 2 diabetes in mice without impacting the reproductive tract

Mass spectrometry and immunoassay: how to measure steroid hormones today and tomorrow

Contact Info

Product

Resources

About